Caspofungin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Caspofungin: From Invasive Fungal Infections to Gastrin Secretion Abnormality
One-Sentence Summary
Caspofungin is an echinocandin-class antifungal agent used for the treatment of invasive fungal infections, including candidiasis and aspergillosis, acting by inhibiting fungal cell wall synthesis. The TxGNN model predicts it may be effective for Gastrin Secretion Abnormality, with a prediction score of 99.44%; however, currently there are 0 clinical trials and 0 publications directly supporting this direction. The mechanistic link between the two conditions is highly speculative, and this prediction should be treated with caution.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Invasive fungal infections (candidiasis, aspergillosis) — based on known pharmacological class; not registered in Taiwan |
| Predicted New Indication | Gastrin Secretion Abnormality |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Caspofungin belongs to the echinocandin class of antifungal agents. Its mechanism of action is the inhibition of β-1,3-glucan synthase (encoded by the FKS1/FKS2 genes), an enzyme essential for fungal cell wall integrity. By disrupting cell wall synthesis, caspofungin exerts fungicidal or fungistatic effects against Candida and Aspergillus species. Detailed MOA documentation from a regulatory source is currently unavailable, which limits confidence in any downstream mechanistic inference.
The predicted new indication — gastrin secretion abnormality — involves the gastrin signalling axis: G-cells in the gastric antrum secrete gastrin, which stimulates enterochromaffin-like (ECL) cells to release histamine, ultimately driving gastric acid secretion. There is no established direct biological intersection between β-1,3-glucan synthase inhibition and the gastrin pathway. Two indirect hypotheses exist: (①) gut mycobiome dysbiosis caused by fungal overgrowth or eradication may indirectly alter enteroendocrine cell signalling; (②) systemic fungal infections can provoke gastrointestinal inflammation that secondarily disrupts gastrin secretion. Both hypotheses are highly speculative and lack supporting preclinical or animal study data.
In summary, while the TxGNN model assigns a high numerical score to this prediction, the biological rationale is weak and the evidentiary base is entirely absent. This prediction is most plausibly a statistical artefact rather than a clinically actionable hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial, observational, or preclinical literature evidence connecting caspofungin to gastrin secretion abnormality, and the mechanistic link is highly speculative. Proceeding without foundational evidence would not represent responsible drug repurposing practice.
To proceed, the following is needed:
- Mechanistic plausibility study: Identify whether any in vitro or animal models demonstrate an effect of echinocandins on gastrin secretion or G-cell function before considering further clinical translation
- MOA documentation: Obtain complete DrugBank MOA data and Taiwan/international package insert to properly characterise the drug's pharmacological profile
- Safety baseline: Retrieve key warnings, contraindications, and DDI profile from the package insert (currently all flagged as data gaps)
- Hypothesis refinement: If the mycobiome-gastrin axis hypothesis is pursued, conduct a targeted literature search on gut fungi and gastrin regulation as an independent step
- Re-evaluation trigger: Return to this candidate only if preclinical mechanistic evidence emerges; until then, deprioritise in favour of higher-evidence repurposing candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.